Research ExplorerPublicationsEuropean trial of free light chain removal by extended haemo...

European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial

Standard

European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. / Hutchison, Colin A; Cook, Mark; Heyne, Nils; Weisel, Katja; Billingham, Lucinda; Bradwell, Arthur; Cockwell, Paul.

In: TRIALS, Vol. 9, 28.09.2008, p. 55.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hutchison, CA, Cook, M, Heyne, N, Weisel, K, Billingham, L, Bradwell, A & Cockwell, P 2008, 'European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial', TRIALS, vol. 9, pp. 55. https://doi.org/10.1186/1745-6215-9-55

APA

Hutchison, C. A., Cook, M., Heyne, N., Weisel, K., Billingham, L., Bradwell, A., & Cockwell, P. (2008). European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. TRIALS, 9, 55. https://doi.org/10.1186/1745-6215-9-55

Vancouver

Hutchison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. TRIALS. 2008 Sep 28;9:55. https://doi.org/10.1186/1745-6215-9-55

Bibtex

@article{97592658074346c98776794c714a9315,
title = "European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial",
abstract = "BACKGROUND: Renal failure is a frequent complication of multiple myeloma and when severe is associated with a greatly increased morbidity and mortality. The principal cause of severe renal failure is cast nephropathy, a direct consequence of high concentrations of monoclonal free light chains (FLCs) in patients' sera. FLC removal by extended haemodialysis, using a high cut-off dialyser, has recently been described as a novel therapeutic option.METHODS: The EUropean trial of free LIght chain removal by exTEnded haemodialysis in cast nephropathy (EuLITE) trial is a prospective, randomised, multicentre, open label clinical trial to investigate the clinical benefits of FLC removal haemodialysis in patients with cast nephropathy, dialysis dependent acute renal failure and de novo multiple myeloma. Recruitment commenced in May 2008. In total, 90 patients will be recruited. Participants will be randomised, centrally, upon enrolment, to either trial chemotherapy and FLC removal haemodialysis or trial chemotherapy and standard high flux haemodialysis. Trial chemotherapy consists of bortezomib, doxorubicin and dexamethasone. FLC removal haemodialysis is undertaken with two Gambro HCO 1100 dialysers in series using an intensive treatment schedule. The primary outcome for the study is independence of dialysis at 3 months. Secondary outcomes are: duration of dialysis, reduction in serum FLC concentrations; myeloma response and survival.HYPOTHESIS: FLC removal haemodialysis will increase the rate of renal recovery in patients with severe renal failure secondary to cast nephropathy in de novo multiple myeloma.TRIAL REGISTRATION: ISRCTN45967602.",
keywords = "Journal Article",
author = "Hutchison, {Colin A} and Mark Cook and Nils Heyne and Katja Weisel and Lucinda Billingham and Arthur Bradwell and Paul Cockwell",
year = "2008",
month = sep,
day = "28",
doi = "10.1186/1745-6215-9-55",
language = "English",
volume = "9",
pages = "55",
journal = "TRIALS",
issn = "1745-6215",
publisher = "Current Controlled Trials Ltd.",

}

RIS

TY - JOUR

T1 - European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial

AU - Hutchison, Colin A

AU - Cook, Mark

AU - Heyne, Nils

AU - Weisel, Katja

AU - Billingham, Lucinda

AU - Bradwell, Arthur

AU - Cockwell, Paul

PY - 2008/9/28

Y1 - 2008/9/28

N2 - BACKGROUND: Renal failure is a frequent complication of multiple myeloma and when severe is associated with a greatly increased morbidity and mortality. The principal cause of severe renal failure is cast nephropathy, a direct consequence of high concentrations of monoclonal free light chains (FLCs) in patients' sera. FLC removal by extended haemodialysis, using a high cut-off dialyser, has recently been described as a novel therapeutic option.METHODS: The EUropean trial of free LIght chain removal by exTEnded haemodialysis in cast nephropathy (EuLITE) trial is a prospective, randomised, multicentre, open label clinical trial to investigate the clinical benefits of FLC removal haemodialysis in patients with cast nephropathy, dialysis dependent acute renal failure and de novo multiple myeloma. Recruitment commenced in May 2008. In total, 90 patients will be recruited. Participants will be randomised, centrally, upon enrolment, to either trial chemotherapy and FLC removal haemodialysis or trial chemotherapy and standard high flux haemodialysis. Trial chemotherapy consists of bortezomib, doxorubicin and dexamethasone. FLC removal haemodialysis is undertaken with two Gambro HCO 1100 dialysers in series using an intensive treatment schedule. The primary outcome for the study is independence of dialysis at 3 months. Secondary outcomes are: duration of dialysis, reduction in serum FLC concentrations; myeloma response and survival.HYPOTHESIS: FLC removal haemodialysis will increase the rate of renal recovery in patients with severe renal failure secondary to cast nephropathy in de novo multiple myeloma.TRIAL REGISTRATION: ISRCTN45967602.

AB - BACKGROUND: Renal failure is a frequent complication of multiple myeloma and when severe is associated with a greatly increased morbidity and mortality. The principal cause of severe renal failure is cast nephropathy, a direct consequence of high concentrations of monoclonal free light chains (FLCs) in patients' sera. FLC removal by extended haemodialysis, using a high cut-off dialyser, has recently been described as a novel therapeutic option.METHODS: The EUropean trial of free LIght chain removal by exTEnded haemodialysis in cast nephropathy (EuLITE) trial is a prospective, randomised, multicentre, open label clinical trial to investigate the clinical benefits of FLC removal haemodialysis in patients with cast nephropathy, dialysis dependent acute renal failure and de novo multiple myeloma. Recruitment commenced in May 2008. In total, 90 patients will be recruited. Participants will be randomised, centrally, upon enrolment, to either trial chemotherapy and FLC removal haemodialysis or trial chemotherapy and standard high flux haemodialysis. Trial chemotherapy consists of bortezomib, doxorubicin and dexamethasone. FLC removal haemodialysis is undertaken with two Gambro HCO 1100 dialysers in series using an intensive treatment schedule. The primary outcome for the study is independence of dialysis at 3 months. Secondary outcomes are: duration of dialysis, reduction in serum FLC concentrations; myeloma response and survival.HYPOTHESIS: FLC removal haemodialysis will increase the rate of renal recovery in patients with severe renal failure secondary to cast nephropathy in de novo multiple myeloma.TRIAL REGISTRATION: ISRCTN45967602.

KW - Journal Article

U2 - 10.1186/1745-6215-9-55

DO - 10.1186/1745-6215-9-55

M3 - SCORING: Journal article

C2 - 18822172

VL - 9

SP - 55

JO - TRIALS

JF - TRIALS

SN - 1745-6215

ER -